ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0182

Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus

Joyce Chang1, Gabrielle Alonzi1, Emily Smitherman2, Pooja Patel3, Gabrielle Morgan4, Livie Huie5, Karen Costenbader6 and Mary Beth Son7, 1Boston Children's Hospital, Boston, MA, 2University of Alabama at Birmingham, Birmingham, AL, 3Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 5University of Alabama at Birmingham, Gardendale, AL, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Division of Immunology, Boston Children's Hospital, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Disease Activity, Disparities, Minority Health, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Racial disparities in outcomes of pediatric SLE (pSLE) have persisted over time. This may be mediated by structural racism, which segregates children belonging to minority groups into neighborhoods with lower childhood opportunity, defined as resources and conditions that promote healthy childhood development across domains of education, socioeconomics, and physical environment. We determined whether lower neighborhood-level opportunity associates with greater disease activity at initial SLE presentation or over time.

Methods: We conducted a cohort study of children newly diagnosed with SLE between 2016-2022, inclusive, in the Boston Children’s Hospital Lupus Registry. The index visit was the first inpatient or outpatient rheumatology encounter with a physician diagnosis of SLE. The primary outcome was the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Geocoded addresses were linked to the Child Opportunity Index 2.0 (2015) by census tract and categorized as: very high, high, moderate, low, or very low opportunity, based on national and state level rankings. Median SLEDAI-2K at the index visit for children in each state-ranked COI category was compared to those living in very high COI areas using Wilcoxon rank sum tests. Associations between COI and disease activity over time were estimated using linear mixed effects models adjusted for time, insurance status, nephritis and neurologic involvement at presentation; additional covariates tested included age at SLE onset, sex assigned at birth, race and ethnicity, non-English primary language, and initial SLEDAI-2K.

Results: We included 644 visits with calculable SLEDAI-2K scores, comprised by 86 patients with pSLE, with a median of 7 visits/patient [2-11] during the study period. The majority of Black (13/18, 72%) and Hispanic children (16/22, 73%) lived in low or very low state-ranked COI areas, whereas a 62% of Non-Hispanic White and 73% of Asian children lived in high or very high COI areas (Figure 1). In this cohort, nationally ranked COI was skewed towards very high (37%) and high (16%) average opportunity (Table 1). Children living in low opportunity areas ranked within state had higher SLEDAI scores at initial presentation compared to patients living in very high opportunity areas (median 14 [6-22] vs. 7 [4-8.5], p=0.03). Living in census tracts with moderate, low or very low COI (vs. very high) associated with significantly higher SLEDAI-2K over time compared to living in very high COI areas, both with or without adjustment for time, insurance status, race and ethnicity, and major organ involvement (Table 2). There was a significant test of trend (p=0.001). Results were similar when adjusting for initial SLEDAI-2K at presentation.

Conclusion: For children with pSLE in an area of the U.S. with high average opportunity levels, lower relative neighborhood-level childhood opportunity associated with higher SLE disease activity at initial presentation to care and during follow-up, independent of initial disease severity. Area-level conditions, among other factors in lower resourced areas, may mediate inequitable outcomes of pSLE at numerous points, including initial access to subspecialty care and after establishing care.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Chang: None; G. Alonzi: None; E. Smitherman: None; P. Patel: AbbVie/Abbott, 12, Site Principal Investagator, Pfizer, 12, Site Principal Investigator; G. Morgan: None; L. Huie: None; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5; M. Son: None.

To cite this abstract in AMA style:

Chang J, Alonzi G, Smitherman E, Patel P, Morgan G, Huie L, Costenbader K, Son M. Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/impact-of-neighborhood-level-child-opportunity-on-disease-activity-in-children-with-lupus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-neighborhood-level-child-opportunity-on-disease-activity-in-children-with-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology